美股
Syntax Bio Closes $14.4M Series A, Adds New CBO and Board Members
Gene editing company Syntax Bio expands its Series A to $14.4 million, appoints a new Chief Business Officer and two independent directors. Funds will advance metabolic disease gene therapy pipeline and technology platform.
YayaNews2026-06-22 04:363 min来源: Seeking Alpha